Add to a list

Inactive Instrument

Seagen Inc. Stock

SGEN

US81181C1045

Biotechnology & Medical Research

Analysts' recommendations: Seagen Inc.

23-12-15	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
23-03-24	Berenberg Bank Downgrades Seagen to Hold From Buy, Adjusts Price Target to $229 From $170	MT
23-03-21	TD Cowen Raises Price Target on Seagen to $229 From $145, Maintains Market Perform Rating	MT
23-03-20	Truist Securities Adjusts Price Target on Seagen to $229 From $152, Maintains Hold Rating	MT
23-03-15	Morgan Stanley Downgrades Seagen to Equalweight From Overweight, Adjusts Price Target to $229 From $173	MT

More recommendations

News in other languages: Seagen Inc.

24-02-05	Übernahmegerüchte schicken Morphosys auf Hoch seit Juli 2021
23-12-15	Pfizer, Inc: un ciclo per niente?
23-12-15	Pfizer : le dividende augmente, le titre rebondit
23-12-15	ÜBERBLICK/Anstehende Indexänderungen
23-12-14	Pfizer, Inc.: een cyclus voor niets?

More news

Managers and Directors: Seagen Inc.

Manager	Title	Age	Since
Chris Boshoff PSD	President	-	2023-12-13
Peggy Pinkston IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Alison Marquez O'Neill BRD	Director/Board Member	-	2023-12-13
Deborah Baron BRD	Director/Board Member	57	2023-12-13

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEAGEN INC.	-0.07%	+4.77%	-	-	43.15B
LONZA GROUP AG	-0.24%	+1.85%	+3.13%	+8.40%	49.74B
REVOLUTION MEDICINES, INC.	-0.66%	+1.08%	+420.14%	+596.58%	40.49B
BEONE MEDICINES AG	-2.33%	+3.18%	+22.71%	+55.81%	34.35B
IQVIA HOLDINGS INC.	-1.93%	+0.20%	+23.79%	-7.21%	34.75B
CELLTRION, INC.	-0.79%	+2.02%	+3.83%	+36.42%	26.98B
ASCENDIS PHARMA A/S	+2.85%	+2.14%	-	-	16.58B
MEDPACE HOLDINGS, INC.	-2.78%	-2.42%	+64.48%	+119.38%	15.6B
IONIS PHARMACEUTICALS, INC.	-2.17%	+6.48%	+103.97%	+101.82%	14.27B
EUROFINS SCIENTIFIC SE	-2.70%	-2.04%	+12.37%	+17.77%	13.76B
Average	-1.23%	+3.99%	+81.80%	+116.12%	27.39B
Weighted average by Cap.	-1.19%	+4.37%	+93.66%	+133.87%

See all sector performances

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Employees

3,256

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SGEN Stock

Google lets you customize your preferred sources.

Choose MarketScreener

24-05-16	Fitch Affirms and Withdraws Pfizer's Ratings; Outlook Stable	AQ
24-03-28	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	AQ
24-02-29	Seagen Requests Director Review Of Unpatentability Decision In Adcetris® Patent PGR	AQ
24-01-30	PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable	AQ
24-01-10	Fitch Affirms Pfizer's Long-Term IDR at 'A'; Outlook Stable	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-12-13	Nancy Simonian	Issuer sale	Director	127,934	0.0678%
23-12-13	John Orwin	Issuer sale	Director	97,934	0.0519%
23-12-13	Charles Romp	Issuer sale	Executive/Senior Manager	225,162	0.1193%

Seagen Inc. Stock

Stocks

SGEN

US81181C1045

Biotechnology & Medical Research

Latest news : Seagen Inc.

Analysts' recommendations: Seagen Inc.

Press Releases: Seagen Inc.

News in other languages: Seagen Inc.

Quotes and Performance

Managers and Directors: Seagen Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

24-02-05	Takeover rumors send Morphosys to high since July 2021	DP
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	CI
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	CI
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	CI
23-12-15	Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	DJ
23-12-15	Pfizer: dividend increases, stock rebounds
23-12-15	Euphoria subsides for Triple-Witching Day
23-12-15	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
23-12-15	HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	MT
23-12-15	Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	CI
23-12-15	Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	CI
23-12-15	Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	CI
23-12-14	Pfizer, Inc: A cycle for nothing?